[Treatment of chronic microvascular complications of diabetes mellitus with aldose reductase inhibitors].
Wajchenberg
B L
BL
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000818:Animals; D002908:Chronic Disease; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000503:physiopathology*; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000503:physiopathology; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005609:Free Radicals / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D006801:Humans; D008833:Microcirculation / Q000503:physiopathology; D009431:Neural Conduction; D018384:Oxidative Stress; D051381:Rats; D012039:Regional Blood Flow
D004791:Enzyme Inhibitors; D005609:Free Radicals; D000449:Aldehyde Reductase; D005947:Glucose